Author: Ryan Allway

The post Valens GroWorks Announces Upsize of Previously Announced Bought Deal Equity Financing to $37.5 Million appeared first on CannabisFN.

The post The Green Organic Dutchman reports year end results appeared first on CannabisFN.

Canopy Growth Corp. in Smiths Falls has nabbed another Ontario cannabis store that will carry the name of one of its brands.

A cannabis lottery winner plans to open a store called Tokyo Smoke 333 Yonge in Toronto, according to a posting Tuesday by the Alcohol and Gaming Commission of Ontario.

Canopy owns the Tokyo Smoke brand. The company already operates four Tokyo Smoke cannabis stores and an e-commerce site in Manitoba.

Tokyo Smoke made an agreement with lottery winner Colin Campbell, who applied to open the store at 333 Yonge St. near Dundas Street West, to use the brand name.

“The lottery winner will have full ownership and control over the Toronto store,” said Canopy spokesperson Caitlin O’Hara in a statement. That’s one of the requirements of the cannabis lottery, held to award the right to apply for the first wave of shop licences.

Another proposed store, in London, will carry the Canopy brand name Tweed.

Only 25 cannabis stores will open across the province this spring. The number was temporarily restricted because of a cannabis shortage.

Licensed cannabis growers such as Tweed were not allowed to enter the lottery. Even when more shop licences are available, growers are restricted from owning more than 9.9 per cent of a retail cannabis store. That was to ensure the retail trade was open to smaller businesses.

However, some of the lottery winners have made licensing and branding deals with cannabis retail chains that operate in other provinces.

Canopy Growth plans to continue expansion of its retail stores under the Tweed and Tokyo Smoke banners. According to a financial statement released in February, the company planned to add 20 additional Tweed and 20 more Tokyo Smoke stores in provinces that allow privately-run shops.

“In the province of Ontario, the company is exploring partnership opportunities to ensure consumers in that market can experience the distinct Tweed and Tokyo Smoke retail experiences,” said the statement.

For the Tweed store in London, Canopy worked in partnership with Couche-Tard, the huge Quebec-based convenience store company. Couche-Tard had a trademark licence agreement with the lottery winner.

The province wanted the 25 cannabis stores to open by April 1. That won’t happen. Three of the lottery winners have not even announced their locations yet.

The public has 15 days to comment after locations are announced, and the licence applicant has another five days to reply.

The deadline for public comment on the Tokyo Smoke 333 Yonge store is April 2.

For another five stores, the public comment period ends between March 19 and March 27, which is tight timing.

Lottery winners had to put up a $50,000 line of credit that will be drawn down if they fail to open on time.

For instance, $12,500 will be charged if the store fails to open April 1, another $12,500 if the doors are not open on April 15 and the remaining $25,000 if it’s not open by the end of April.

Canopy Growth’s retail stores

Canopy Growth in Smiths Falls has a growing arm of retail stores:

Tokyo Smoke: Canopy bought Tokyo’s Smoke’s parent company last summer. Tokyo Smoke started life as a small chain of trendy cafes that sold coffee, cannabis accessories and clothes, and has expanded to include stores that sell cannabis.

There are four Tokyo Smoke cannabis stores and one e-commerce site in Manitoba; five Tokyo Smoke coffee shops in Toronto and one in Calgary; and an education centre in Vancouver.

An Ontario lottery winner has proposed using the name Tokyo Smoke 333 Yonge on a store in Toronto.

Canopy planned to add another 20 Tokyo Smoke cannabis stores, according to its financial statements released in February.

Tweed: Canopy Growth subsidiary Tweed is the company’s most well known brand. Tweed is the name of the licensed grower in Smiths Falls and is also a brand name of recreational weed sold across Canada.

Canopy operates 10 Tweed stores in Newfoundland & Labrador and Manitoba, and has a licensing agreement with a store in Saskatchewan to use the name. An Ontario lottery winner has an agreement to use the Tweed brand on a store proposed for London. Tweed also sells cannabis on e-commerce sites in Manitoba and Nunavut.

The company planned to add another 20 Tweed stores, according to its February financial statements.

The post Canopy Growth lands a cannabis store in Toronto opening under its Tokyo Smoke brand name appeared first on CannabisFN.

SMITHS FALLS, ON and VICTORIA, BC, March 20, 2019 /CNW/ – Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) and HollyWeed Manufacturing & Extracts Inc. are pleased to announce today they have entered into a multi-year processing and extraction agreement. HollyWeed North Cannabis Inc., the parent company of HollyWeed Manufacturing & Extracts Inc., is a female-led, LGBTQ2-positive company based in British Columbia that operates several subsidiaries specializing in the growth, manufacturing, licensing, and production of cannabis and other pharmaceutical grade products.

Under the terms of the two-year agreement, HollyWeed Manufacturing & Extracts Inc. will process dried cannabis provided by Canopy Growth, in their advanced manufacturing facility in Victoria and will return the high-quality oil and resin back to the Company. The increased supply of this contracted extraction throughput adds to the Company’s in-house capacity and supports Canopy Growth with additional throughput as it brings a suite of new products to the market later this calendar year. The extraction services provided by HollyWeed will build on the Company’s own in-house manufacturing and production based in Smiths Falls, Ontario and will extend Canopy Growth’s production commitment in British Columbia, where it currently has more than three million square feet of fully operational grow space located in Delta and Aldergrove.

“This is an opportunity for Canopy Growth to build a strong partnership with another high-quality Canadian company. The cannabis resin we get from HollyWeed will be used for our current offering of oils and softgels, as well as our future advanced manufacturing products,” said Bruce Linton, Chairman and co-CEO of Canopy Growth. “Ensuring we continue to offer the highest quality cannabis oil and resin will be essential for our entry into the edibles market and supports our overall goal of making a wide variety of high-quality products available to our customers.”

“We are very excited to provide extraction services to Canopy Growth, a global leader in cannabis production,” remarked Renée Gagnon, CEO of HollyWeed North Cannabis Inc. “We are incredibly proud that the quality of our proprietary extraction process caught the eye of an industry leader like Canopy Growth and will amplify their own world-leading extraction abilities. This is definitely a new and exciting chapter for HollyWeed.”

HollyWeed and Canopy Growth expect the first shipment of product for extraction will occur in fall 2019 and anticipate being able to leverage the resin shortly thereafter.

Here’s to Future (West Coast) Growth.

About HollyWeed North Cannabis Inc. 87
HollyWeed North is a private Canadian company incorporated in British Columbia, established in 2016, with operating subsidiaries specializing in the growth, manufacturing, licensing and production of cannabis and other pharma grade products. HollyWeed North’s subsidiaries include HollyWeed Manufacturing and Extracts Inc., a Standard Processing licensed company incorporated in British Columbia specializing in cannabis extraction and product manufacturing; HollyWeed Grow Inc., a late stage federal ACMPR applicant, also a private company incorporated in British Columbia specializing in the growth of medical cannabis and cannabis products; HollyWeed Retail Inc., a retail strategies provider and supply chain management company incorporated in British Columbia; HollyWeed Bakery Inc., a developer and manufacturer of unique cannabis baked goods and edibles incorporated in British Columbia; and TerraCube International Inc., a manufacturer and developer of proprietary scalable, sanitary grow facilities incorporated in British Columbia. HollyWeed North is currently restructuring its capital such that, upon execution of the Definitive Agreement, all the subsidiaries will be wholly-owned by HollyWeed North.

About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company’s subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.

The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations (“Canopy Health”), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. (“ebbu”). Intellectual Property (“IP”) and R&D advancements achieved by ebbu’s team apply directly to Canopy Growth’s hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector.

From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world’s largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit www.canopygrowth.com.

Notice Regarding Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include “HollyWeed and Canopy Growth expect the first shipment of product for extraction will occur in fall 2019 and anticipate being able to leverage the resin shortly thereafter”. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including future products, and such risks contained in the Company’s annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.

SOURCE Canopy Growth Corporation

For further information: Media Relations, Caitlin O’Hara, Caitlin.Ohara@canopygrowth.com, 613-291-3239; Investor Relations, Tyler Burns, Tyler.Burns@canopygrowth.com, 855-558-9333 ext. 122; Hollyweed Contact: Leslie Gerard, Chief Marketing Officer, leslie@hollyweednorth.com, 310-897-1955

Related Links

canopygrowth.com

The post Canopy Growth announces multi-year extraction agreement with Victoria-based HollyWeed North Cannabis Inc. appeared first on CannabisFN.

VANCOUVER, March 20, 2019 /CNW/ – AgraFlora Organics International Inc. (“AgraFlora“) (the “Company“) (CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF), a growth oriented and diversified international cannabis company, is pleased to announce it is acquiring an additional 10% of the shares of Propagation Services Canada Inc. (“PSC“) for $14 million payable by common shares of AgraFlora at a price of $0.68 per share, equivalent to 20,588,235 common shares. The transaction has been agreed to in principle and approved by both boards of directors of AgraFlora and PSC. Following the transaction, the ownership of PSC will consist of AgraFlora as to 60%, the Houwelings Partnership Group as to 30% and the investors of Delta Organics Cannabis Corp. (“DOCC“) as to 10%.

“It is important for AgraFlora to continue to have a majority stake in the joint venture company Propagation Services Canada,” said Derek Ivany, President and CEO of AgraFlora. “The Delta Greenhouse Complex will become our marquee facility with 2.1 million square feet of greenhouse space and 100,000 square feet in production facilities. Progress on the retrofit continues to be on target and we expect to submit our licensing application video to Health Canada by the end of June.”

AgraFlora is issuing common shares at $0.68 per share which is an approximate 53% premium to the shares paid to DOCC at $0.445 for its 20% purchase of PSC, as announced in November 2018. The 10% acquired by AgraFlora comes from four shareholders of PSC who have shown confidence in the AgraFlora management team by converting their PSC shares into shares of AgraFlora. This is an arm’s length transaction and no finder’s fees are to be paid.

Upon closing the final $20 million payment of a previously announced financing, DOCC will receive an additional 10% from AgraFlora and AgraFlora will remain the majority shareholder with a 50% ownership position of PSC, with the Houwelings Partnership Group with 30% and the investors of DOCC with 20%. AgraFlora’s 50% ownership of PSC will entitle it to 50% of the annual estimated production of 250,000,000 grams from the Delta Greenhouse Complex.

About Propagation Services Canada Inc.

Propagation Services Canada is a joint venture company focused on the cannabis flower and propagation market in Canada. Its Delta Greenhouse Complex covers approximately 2.2 million square feet and is one of the most technologically advanced greenhouses in North America, with an experienced staff, full propagation services, advanced HVAC, lighting and water systems and its own 8.8 MW powerplant.

About AgraFlora Organics International Inc.

AgraFlora Organics International Inc. is a growth oriented and diversified company focused on the international cannabis industry. It owns an indoor cultivation operation in London, ON and is a joint venture partner in Propagation Service Canada Inc. and its large-scale 2,200,000 sq. ft. greenhouse complex in Delta, BC. The Company has a successful record of creating shareholder value and is actively pursuing other opportunities within the cannabis industry. For more information please visit: www.agraflora.com.

ON BEHALF OF THE BOARD OF DIRECTORS

Derek Ivany
President & CEO

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.

SOURCE AgraFlora Organics International Inc.

For further information: AgraFlora Organics International Inc., Tim McNulty, E: ir@agraflora.com, T: (800) 783-6056 | For French inquiries: Maricom Inc., Remy Scalabrini, E: rs@maricom.ca, T: (888) 585-MARI

Related Links

www.pufventures.com

The post AgraFlora Organics Increases Ownership Position in Propagation Services Canada Inc. appeared first on CannabisFN.

TORONTO, March 19, 2019 (GLOBE NEWSWIRE) — Eve & Co Incorporated (“Eve & Co” or the “Company”) (TSX-V: EVE; OTCQB: EEVVF) is pleased to announce that Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd. (“NMC”), has entered into an $18,700,000 construction facility with Royal Bank of Canada (the “Lender”) to fund the completion of the 780,000 sq. ft. expansion of its greenhouse production facility located in Middlesex County, Ontario.  After completion of the expansion which is expected by the end of Q2 2019, it is contemplated that the construction facility will be replaced with a non-revolving term facility.  Interest on the facilities will float at a rate of 1.00% per annum above the Lender’s prime lending rate, which currently is 3.95% per annum.

The obligations under the facilities will be guaranteed by Eve & Co and will be primarily secured by a collateral mortgage on NMC’s property located in Middlesex County.  The facilities are subject to certain customary financial and other covenants for a financing of this type and advances under the facilities are subject to certain customary conditions precedent.

“This transaction is a strong validation of Eve’s efforts to build a leading cannabis company. This non-dilutive financing will help complete the ongoing expansion of our facility from 220,000 sq. ft. to 1,000,000 sq. ft., making Eve one of the largest producers in Canada. We are thrilled to have the Royal Bank of Canada, one of the world’s pre-eminent financial institutions, supporting our work that will assist us to grow the Eve brand and expand our global footprint,” stated Melinda Rombouts, CEO of Eve & Co.

The Company also announced today that the Board of Directors has appointed Davidson & Company LLP as the Company’s new auditor, replacing MNP LLP. The Company has filed a Notice of Change of Auditor in respect of this change under its profile on SEDAR at www.sedar.com.

About Eve & Co Incorporated

Eve & Co, through its wholly-owned subsidiary Natural MedCo Ltd., holds cultivation and processing licenses under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and cannabis oil. Natural MedCo Ltd. was Canada’s first female founded licensed producer of medicinal marijuana and received its cultivation license from Health Canada in 2016.

Eve & Co is led by a team of agricultural experts and has a licenced 220,000 sq. ft. scalable greenhouse production facility located in Middlesex County, Ontario with 32 acres of adjacent land for future expansion. Eve & Co has commenced construction of an additional 780,000 sq. ft. proposed expansion, bringing Eve & Co’s total anticipated greenhouse capacity to 1,000,000 sq. ft.

The Company’s website can be visited at www.evecannabis.ca

Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the terms of the credit facilities and the Company’s related expansion and construction plans, future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. These statements are not historical facts but instead represent only the Company’s expectations, estimates and projections regarding future events. These statements are not guarantees of future performance and involve assumptions, risks and uncertainties that are difficult to predict, including those described in the Company’s management’s discussion and analysis for the three and twelve months ended October 31, 2018 which is available on the Company’s SEDAR profile. Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities law.

For further information, please contact:

The post Eve & Co Enters Into Credit Facility With Royal Bank of Canada to Fund Expansion of Its Greenhouse Production Facility appeared first on CannabisFN.

February 27, 2019 – Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTCQB:ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) today announced the launch of its convenience store (C-Store) retail program into the first 1,250 locations, starting in markets such as Florida and Arizona, through its partnership with the Asian American Trade Associations Council (AATAC).  Once the initial test rolls out and is approved for expansion by AATAC, Isodiol will be able to expand up to 10,000 additional locations.  The Company will launch its Fast CBD Relief brand that it recently acquired with the CBD Naturals® brands portfolio as its flagship cannabinoid (CBD) products in the C-Store program.  This new retail effort is further to the Company’s previous announcement on February 14, 2019.

The Fast CBD Relief products were launched in mid-2018 as a solution for millions of Americans struggling with pain and other lifestyle discomforts. According to the American Academy of Pain Medicine, 100 million people face chronic pain, which affects more Americans than diabetes, heart disease, and cancer combined[1].

Fast CBD Relief is available in the following forms:

• ‘The Patch’: The patch delivers fast and targeted pain relief and can be cut to size and applied to the area needed, delivering relief up to 12 hours;
• ‘The Cream’: Ideal for smaller areas of discomfort, this cooling cream supplies instant relief and can be applied to fingers, knees, ankles, neck, and any other areas of discomfort;
• ‘The Shot’: A concentrated beverage in four varieties that taste great and target specific issues, including RESCUE (relieves tension), SLEEP (promotes rest), IMMUNE (boosts immunity), and FOCUS (enhances concentration); and
• ‘The Roll-On’: Promoting a sense of calm and relaxation, this topical serum is fast and effective.

All of the Fast CBD Relief products contain phytocannabinoids along with other terpenes or botanicals that work synergistically to create an entourage effect for greater results. They also include other powerful supportive ingredients such as extracts, vitamins, and essential oils that are known to provide positive health and wellness benefits to the body and mind.

“Isodiol’s new C-Store program marks a significant milestone in the Company’s ongoing push into the mainstream Consumer Packaged Goods (CPG) market,” said Isodiol’s Chief Revenue Officer, Kevin Swadish. “C-Store owners have long been considered the heart and soul of the retail market, touching virtually every person in every walk of life and representing the very essence of entrepreneurial spirit.  The natural fit was to work with the largest trade association of retailers in the USA for this retail vertical.  It simply makes sense for Isodiol to embrace the market power of this retail channel, and we expect great things from our partnership with AATAC and the mass retail launch of the Fast CBD Relief brand from the CBD Naturals® brands portfolio.”

Paul Rock, Board of Directors Trustee of AATAC, added, “We have been working closely with Isodiol’s current management and design team since before the recent federal regulatory developments that are opening the U.S. to vast new retail opportunities for CBD products.  As anticipated, we are already seeing tremendous interest and growth of these products and huge success with early tests.  This proves to us that we are entering a new age of CBD products with CBD as an accepted, prolific ingredient and will need strong partners like Isodiol to help us navigate the waters ahead.  The association will now be taking a step back and limiting who we work with for this product offering and educate our retailers on what to look for in good CBD products and companies.  Isodiol will be a great asset in determining the most appealing CBD product formats for our retail partners and supplying those products going forward.”

Follow Our Corporate Updates On Facebook at www.facebook.com/IsodiolInternationalInc/, on Twitter @Isodiolintlinc, and on Instagram @isodiol.

About Isodiol International Inc.

Isodiol International Inc. is focused on the nutritional health benefits that are derived from hemp and is a product development, sales, marketing and distribution company of hemp-based Consumer Packaged Goods (CPG) and solutions. Isodiol has commercialized a 99%+ pure, naturally isolated CBD, including micro-encapsulations, and nano-technology for quality consumable and topical skin care products. The Company received approval for its CBD as an Active Pharmaceutical Ingredient (API) for use in Finished Pharmaceutical Products (FPPs), as was announced on April 26, 2018.  Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe through the proliferation of its various brands, including the recently acquired CBD Naturals® portfolio of brands and proprietary technologies.

About Asian American Trade Associations Council (AATAC)

The Asian American Trade Associations Council (AATAC) is composed of delegates from various business retailer groups across the country with each group having as few as a 100 or as many as 10,000 or more retail locations. The aggregate reach of AATAC is 90,000+ retail locations in the corner store, convenience store, and gas station (C-Store) industry.  AATAC’s primary and affiliate members operate many franchises of the most popular branded C-Store retailers such as 7-11, Circle K, Sunoco, Chevron, 76, BP, Arco, ampm, Kangaroo, Shell, Marathon, and many others.  AATAC was reshaped in 2012 to cohesively aggregate the purchasing power, bargaining ability, and regulatory feedback that are required to excel in the retailing industry across multiple sectors throughout North America. AATAC also is backed by the power of an implementation company and a marketing division that not only increases the reach and placement of products and services, but also can launch and build entire brands within the industry. AATAC conducts and conducts private tradeshows, dinners, events, gatherings, and face-to-face program implementations, providing its corporate partners with direct access to retail location owners and management and leading to a competitive advantage within the marketplace.   The overall C-Store industry reaches more Americans daily than grocery, drugstore, dollar store, and big box stores combined.

ON BEHALF OF THE BOARD

Marcos Agramont, CEO & Director

INVESTOR RELATIONS:

Ir@isodiol.com
604-409-4409

MEDIA CONTACT:

Christopher Hussey
media@isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, proposed arrangement with creditors, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

The post Isodiol International Inc. Announces Launch of Convenience Store Retail Program into Thousands of Locations Nationwide, Starting with Florida and Arizona Through its Partnership with the Asian American Trade Associations Council (AATAC) appeared first on CannabisFN.

VANCOUVER, British Columbia, March 20, 2019 /PRNewswire/ — MYM Nutraceuticals Inc., (CSE: MYM) (OTCBB: MYMMF) (CSE: MYM.CN) (MYM.CN)  (“MYM” or “The Company”) is pleased to announce that it has increased its stake in Colombia Organica to 80%.

Colombia Organica currently holds 3 licenses which include: production of cannabis derivatives, cultivation of psychoactive cannabis, and cultivation of non-psychoactive cannabis. Licenses include the capacity to export. Colombia Organica has submitted an application to certify cannabis seeds for commercialization. In addition, it holds a lease for a 36-acre property located 44 kms from Medellin. The region’s climate is conducive for growing cannabis with an average temperature of 16-18 °C, and an elevation of 2,475 meters above sea-level. They have secured an option to buy the property.

MYM and Colombia Organica are building a production facility near Medellin, Colombia for the cultivation and processing of cannabis and cannabis products. Currently, Colombia Organica is developing and registering seed strains with the Colombian Agricultural Institute.

MYM will acquire eighty 80% of Colombia Organica  from its existing shareholders for consideration of cash, equity and loans to the company for a total package of up to $2.26 million. MYM will employ Colombia Organica principals Daniel Alonso and Gabriel Ramirez as Territory Managers for South American operations.

“After further review we’ve decided to increase our stake in Colombia Organica under much more favourable terms”, said Howard Steinberg, CEO of MYM. “Colombia presents an exciting opportunity for MYM to expand its cultivation operations into South America, bringing with it increased value to our shareholders. The addition of Daniel and Gabriel to our team will provide the company with boots on the ground for all current and future projects in South America“.

The Investment Agreement is subject to all required approvals and MYM’s due diligence.

About Colombia Organica

Colombia Organica is a Colombian company with expertise in the manufacture of pharmaceutical products, medicinal chemical substances and botanical products. Colombia Organica currently holds 3 licenses which include: production of THC cannabis derivatives, cultivation of psychoactive cannabis, and cultivation of non-psychoactive cannabis, including exportation. Colombia Organica has selected for production high quality plants which are suited to the unique high altitude, equatorial regions of Antioquia, Colombia.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on the global growth of cannabis and hemp.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors.  MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC: MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

Keep up to date with MYM on our social media channels:

Twitter: @mymnutra

Facebook: @mymnutra

Instagram: @mymnutra

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States“, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

ON BEHALF OF THE BOARD

Howard Steinberg, CEO  
MYM Nutraceuticals Inc.
www.mym.ca

Investor Relations 
Billy Casselman  
778-522-2261 
investors@mym.ca

SOURCE MYM Nutraceuticals Inc.

Related Links

https://www.mym.ca/

The post MYM Increases Stake in Colombia Organica to 80% appeared first on CannabisFN.

VANCOUVER and SAN DIEGO, CA, March 20, 2019 /CNW/ – Phivida Holdings Inc. (CSE: VIDA OTCQX: PHVAF) (“Phivida” or the “Company”), today has entered into a strategic partnership with Green Glass Global, a leading beverage brokerage firm specializing in on premise national accounts for the specialty drinks sector. The partnership will focus on placing Phivida’s Oki beverages in premium hospitality outlets across the U.S.

“We are really excited to partner with Green Glass Global to represent our Oki beverage brand nationally in the on-premise channel,” said Doug Campbell, Chief Commercial Officer at Phivida. “The on-premise channel represents a significant strategic opportunity for us to gain listings in the very best restaurants, hotels, gyms, cafes and bars in the country – all areas that are great opportunities to build trial and awareness for our Oki brand. Bob McLachlan and his team are some of the best in the business in this channel, and we are excited to be working with them in this exciting new category.”

Green Glass Global is a beverage brokerage house that represents various well-known wine, spirit and specialty beverage brands in the U.S. The company’s growing sales team provides national representation for its clients. Collectively, the team has more than 250 years of beverage sales experience, with well-established relationships with top multi-unit accounts, both small and large, throughout the United States.

“We have an incredibly diverse and talented collection of brokers on this team and we could not be more excited to represent Oki and help expose this extraordinary brand to some of the most important buyers in country,” Said Bob McLachlan, National Sales Lead at Green Glass Global.

From national restaurant and hotel chains to cruise lines, drug stores, health clubs and military, the beverage team of Green Glass Global possess strong relationships that will open doors and leverage opportunities.

For more information on Phivida products, please visit www.feelOki.com and www.hempvidaplus.com

ABOUT GREEN GLASS GLOBAL 
Founded in January 2018 by two industry veterans Ben Salisbury and Bob McLachlan, Green Glass Global is a “modern” beverage broker model.  Their fast-growing team leverages long-standing relationships with major accounts across all channels of trade to build high quality distribution for their clients. For more information, visit www.greenglassglobal.com

ABOUT Phivida Holdings Inc.
Phivida Holdings Inc. is headquartered in Vancouver, BC with operations in San Diego CA. Phivida is a premium functional food and beverage company focused on whole plant nutrition and natural ingredients that help best maintain overall health and balance in the human body. The company infuses organic active hemp extract into a variety of premium beverages and clinical products for everyday health. Phivida embraces and celebrates a return to organic, natural, plant-based foods and beverages, and a focus on holistic health and wellness. The mission is to help reduce the world’s dependence on pharmaceuticals and provide food and beverage choices that allow customers to live a balanced, healthy lifestyle. For more information, visit phivida.com.

SOURCE Phivida Holdings Inc.

For further information: Website www.phivida.com, Toll free +1 (844) 744-6646 (ext. #2), Email IR@phivida.com; Jim Bailey, President and CEO, Phivida Holdings Inc., +1 (844) 744-6646; Investor Relations: Craig MacPhail, NATIONAL Capital Markets, 416-586-1938, cmacphail@national.ca; Media Relations: Amie Lauder, NATIONAL Capital Markets, 416-586-1943, alauder@national.ca

Related Links

www.phivida.com

The post Phivida and Green Glass Global Announce U.S. Partnership with Oki Beverage Line appeared first on CannabisFN.

CHICAGO, March 19, 2019 /PRNewswire/ — Grassroots Cannabis (“Grassroots” or the “Company”), a cannabis company that grows, processes and sells cannabis through its multi-state, vertically integrated business model announces the successful completion of its first capital raise of $90,000,000 at the GR Companies Inc. (holdco) level.

The Company launched its convertible note financing round on December 3, 2018, with the intent to raise at least $40,000,000 in proceeds. Due to strong demand from both existing shareholders and new investors—including high-net-worth individuals, family offices, cannabis private equity funds and institutions—the financing round was ultimately increased to accommodate $90,000,000 of subscriptions. In completing this financing with strong support from both Beacon Securities, Ltd. and Stoic Advisory, Inc., in its capacity as a strategic advisor to management, Grassroots expanded the geographic dispersion of its investors considerably, with investors domiciled in the U.S., Canada, Europe, Israel and China participating.

By successfully completing this round of funding, Grassroots has solidified its already strong financial position, which includes $165,000,000 of total equity and equity-linked securities raised to date.

“We believe this capital raise now makes Grassroots the largest privately held cannabis company in the U.S.,” said Mitch Kahn, CEO and Co-Founder. “Our growth is a testament to our team’s collective strategic vision and execution of building an integrated business model that enhances the communities which we serve.”

The planned use of the proceeds from the convertible note raise will support the build-out of Grassroots existing 11 state platform, as well as M&A and growth initiatives, including: Expansion of the Company’s cultivation facilities in Illinois, Maryland and Pennsylvania in tandem with strong growth the company is experiencing in these markets.

Build-out of new dispensary licenses won by the Company in December and January.
Funding associated with Grassroots recent strategic partnership with Phyto Science Management Group in Vermont to expand its cultivation and lab capacity, as well as expansion in its CBD derived from hemp business.
Additional M&A opportunities targeting both new markets and expansion in existing markets.

“This is a very exciting time for Grassroots given that we have expanded our footprint in the last three months from seven states to now encompass 11 states and growing,” said Brian Schinderle, Executive Vice President of Finance. “We would like to thank the strong support we saw from both existing and new investors and look forward to continuing to earn their allegiance by both executing on our existing plans and looking to prudently continue to expand our platform.”

Grassroots is a cannabis company born in Illinois and committed to growing from the ground up, working locally—state by state—to create jobs and opportunity while serving, advancing and respecting the cannabis movement. Grassroots began 2014 with two employees and currently has more than 400 employees. Recently Grassroots has brought on Lisa Hurwitz, Chief Marketing and Innovation Officer, to further Grassroots portfolio of products and Brian Schinderle, Executive Vice President of Finance, to focus on strategy, M&A and capital markets activities. The company will continue to build its human infrastructure in key areas to support its rapid expansion.

About Grassroots Cannabis
GR Companies Inc. (dba Grassroots Cannabis) is a cannabis company dedicated to serving, advancing and respecting the cannabis movement. Through its unique, vertically integrated business model, Grassroots grows, processes and sells trusted cannabis products that enhance life’s moments for people from all backgrounds. Its retail brand, Herbology, offers a unique, wellness and education-focused dispensary experience.

Grassroots Cannabis logo

Grassroots Cannabis has built its portfolio at an unprecedented pace, with facilities in highly competitive markets, including Illinois, Nevada, Pennsylvania, Michigan, Maryland, Oklahoma, Ohio, Vermont, North Dakota, Arkansas and Connecticut. The company is pursuing acquisitions in additional markets. The executive management team is composed of a group of highly skilled business leaders united by a common belief: Cannabis inspires us to live deeply. For more information, visit grassrootscannabis.com.
SOURCE Grassroots Cannabis
Related Links
www.grassrootscannabis.com

The post Grassroots Cannabis Announces Closing of US $90M Capital Raise appeared first on CannabisFN.

NANAIMO, British Columbia–(BUSINESS WIRE)–Tilray, Inc., (“Tilray” or the “Company”) (Nasdaq: TLRY) a global leader in cannabis research, cultivation, production and distribution, today reported financial results for the fourth quarter and year ended December 31, 2018. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.

“Looking ahead, we remain committed to pursuing global growth opportunities and will be disciplined in deploying capital, particularly in the United States and Europe, where we believe we have multiple paths for value creation.”

Tweet this

“2018 was a very successful year for Tilray with many corporate milestones. Our team made significant progress on our long-term initiatives including increasing production capacity, expanding and strengthening strategic partnerships, and acquiring complementary businesses to accelerate our future growth and leadership position in medical and adult-use cannabis,” commented Brendan Kennedy, President and Chief Executive Officer of Tilray. “Looking ahead, we remain committed to pursuing global growth opportunities and will be disciplined in deploying capital, particularly in the United States and Europe, where we believe we have multiple paths for value creation.”

2018 Financial Highlights

• Revenue increased to $43.1 (C$56.4) million, up 110.0% compared to last year. The increase in revenue was driven by bulk sales, the inaugural sales for the Canadian adult-use market and accelerated wholesale distribution in export markets.
• Total kilogram equivalents sold increased over two-fold to 6,478 kilograms from 3,024 kilograms in the prior year.
• Average net selling price per gram increased to $6.61 (C$8.59) compared to $6.52 (C$8.42) in the prior year. In 2018, there was significant revenue growth for extract products compared to dried flower, where extracts represented 49% of the sales mix in 2018 compared to 20% in 2017.
• Net loss for the year was $67.7 million, or $0.82 per share, compared to $7.8 million, or $0.10 per share, for 2017. Net loss includes non-cash stock-based compensation charges of $21.0 million compared to a $0.1 million charge in the prior-year. Adjusted EBITDA was a loss of $33.1 million compared to a loss of $5.5 million the prior year. The increased net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to continued growth, expansion of international teams, and costs related to financings and the initial public offering (“IPO”). See “Use of Non-U.S. GAAP Financial Measures.”

Fourth Quarter 2018 Financial Highlights

• Revenue increased to $15.5 (C$20.9) million, up 203.8% compared to the fourth quarter of last year, driven by bulk sales, inaugural sales in the Canadian adult-use market and accelerated wholesale distribution in export markets.
• Total kilogram equivalents sold increased almost three-fold to 2,053 kilograms from 694 kilograms in the prior year period.
• Average net selling price per gram increased to $7.52 (C$10.05) compared to $7.13 (C$9.12) in the prior year period.
• Net loss for the quarter was $31.0 million or $0.33 per share compared to $3.0 million or $0.04 per share for the prior year period. Net loss includes non-cash stock-based compensation charges of $4.1 million compared to $34 thousand in the prior year period. Adjusted EBITDA was a loss of $17.8 million compared to a loss of $2.1 million the prior year period. The increased net loss and Adjusted EBITDA declines were primarily due to the increase in operating expenses related to growth initiatives, expansion of international teams and costs related to financings and M&A activities.

Business Highlights

• Expanded strategic alliance with Sandoz, a Novartis Division, globally to increase access to medical cannabis products to patients in need across the world.
• Announced research and development partnership with AB InBev focused on non-alcohol THC and CBD beverages. Each company intends to invest up to $50 million, for a total of up to $100 million.
• Announced a long-term revenue sharing agreement with Authentic Brands Group (“ABG”) to leverage their portfolio of brands and develop, market and distribute consumer cannabis products across the world. This global partnership will focus on CBD products in the United States and THC/CBD products in Canada, and elsewhere as regulations permit.¹
• Acquired Manitoba Harvest, a hemp and natural foods producer in Winnipeg, Manitoba, for up to $317 (C$419) million, subject to certain revenue milestones. Manitoba Harvest distributes its products to over 16,000 retail locations in the United States and Canada.²
• Acquired Natura Naturals Holdings Inc., a licensed cannabis cultivation facility in Leamington, Ontario, for up to $53.4 (C$70.0) million, subject to certain cultivation milestones.³
• Invested $5.7 (C$7.5) million in Quebec-based cannabis producer ROSE Lifescience Inc. and entered into a sale, supply, distribution, and marketing agreement for ROSE to deliver adult-use cannabis products in Québec.
• Acquired Alef Biotechnology SpA, a licensed cannabis company in Chile, which will allow Tilray to import, produce and distribute Tilray branded medical cannabis throughout Latin America.
• Signed Supply Agreement for Hemp-Derived CBD from LiveWell Canada, which will be sourced from the United States and Canada and be used for wellness and medical products across North America.
• Partnered with researchers at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney to complete a study examining the effects of cannabis on driving and cognitive function.
• Formed an International Advisory Board to provide guidance to the Company’s executive team and Board of Directors on global expansion.
• Expanded global senior leadership team with six strategic hires: Andrew Pucher as Chief Corporate Development Officer; Greg Christopher as EVP of Operations; Rita Seguin as EVP of Human Resources; Dara Redler as General Counsel; Charlie Cain as VP of Retail; and Sascha Mielcarek as Managing Director Europe.⁴
• Completed a successful harvest of medical cannabis at the Company’s European Union campus in Portugal and expect multiple harvests in the coming months.⁵

Conference Call

The Company will host a conference call to discuss these results today at 5:00 p.m. ET. Investors interested in participating in the live call can dial 877-489-6528 from the United States and 629-228-0736 internationally. A telephone replay will be available approximately two hours after the call concludes through Monday, April 1, 2019, by dialing 855-859-2056 from the United States, or 404-537-3406 from international locations and entering confirmation code 6093459.

There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at www.tilray.com. The webcast will be archived for 30 days.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.

Forward Looking Statements

This press release contains “forward-looking statements”, which may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. including statements regarding our growth potential, the sustainability of growth, demand for our products and the medical and adult-use cannabis markets and anticipated plans for strategic partnerships. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market conditions. Actual results, performance or achievement could differ materially from that expressed in, or implied by, any forward-looking statements in this press release, and, accordingly, you should not place undue reliance on any such forward-looking statements and they are not guarantees of future results. Forward-looking statements involve significant risks, assumptions, uncertainties and other factors that may cause actual future results or anticipated events to differ materially from those expressed or implied in any forward-looking statements. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 14, 2018, for a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. Tilray does not undertake to update any forward-looking statements that are included herein, except in accordance with applicable securities laws.

Use of Non-U.S. GAAP Financial Measures

To supplement its financial statements, the Company provides investors with information related to Adjusted EBITDA, which is not a financial measure calculated in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Adjusted EBITDA is calculated as net income (loss) before interest expense, net; other (income), net; deferred income tax recovery, tax expense; foreign exchange (gain) loss; depreciation and amortization; and stock-based compensation expense. A reconciliation of Adjusted EBITDA to net loss, the most directly comparable GAAP measure, has been provided in the financial statement tables included below in this press release. The Company believes Adjusted EBITDA provides useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. Management uses Adjusted EBITDA to compare the Company’s performance to that of prior periods for trend analyses and planning purposes. Adjusted EBITDA is also presented to the Company’s Board of Directors.

Non-U.S. GAAP measures should not be considered a substitute for, or superior to, financial measures calculated in accordance with U.S. GAAP. Non-U.S. GAAP measures exclude significant expenses that are required by U.S. GAAP to be recorded in the Company’s financial statements and are subject to inherent limitations.

____________________________

¹ Announced January 14, 2019
² Announced February 20, 2019
³ Announced February 19, 2019
⁴ Announcements made on January 31, 2019, February 7, 2019 and March 18, 2019
⁵ Announced March 6, 2019

The post Tilray, Inc. Reports Full Year 2018 Financial Results appeared first on CannabisFN.

SMITHS FALLS, ON and LOS ANGELES, CA, March 19, 2019 /PRNewswire/ – Canopy Growth Corporation (“Canopy”) (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”), a world-leading, diversified cannabis company and OG DNA Genetics (“DNA”), a globally recognized cannabis brand, are pleased to announce today they have signed an agreement to extend and expand upon their previously announced partnership through to 2024.  With this newly signed agreement, Canopy Growth and DNA have extended their partnership beyond Canada and Jamaica and have committed to bringing DNA’s world-renowned genetics to a soon-to-be disclosed European market.

The post Canopy Growth and DNA Genetics Extend and Expand Relationship appeared first on CannabisFN.

TORONTO and RIONEGRO, Colombia, March 19, 2019 /CNW/ – PharmaCielo Ltd. (“PharmaCielo” or the “Company“) (TSXV:PCLO), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis oil, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the Company has received the ISO 9001:2015 certification for its cultivation and extraction operations.

The post PharmaCielo Receives ISO 9001 Quality Assurance Certification for Its Medicinal Cannabis Cultivation and Processing Operations in Colombia appeared first on CannabisFN.

VANCOUVER, March 19, 2019 /CNW/ – Zenabis Global Inc. (“Zenabis”) (TSXV: ZENA) has signed its first exclusive, definitive supply agreement under its Zen Craft Grow program. This first Zen Craft Grow agreement is an exclusive supply agreement between Zenabis, as a standard processor, and a micro-cultivator in the final stages of receiving its license that will bring unique genetics and small-batch, artisanally grown cannabis to discerning adult-use consumers across Canada.

The Zen Craft Grow program reflects Zenabis’ ongoing commitment to offer consumers a range of unique and high-quality products. Through the Zen Craft Grow program, Zenabis provides its regulatory, compliance and quality control expertise to facilitate the licensing of small-scale craft growers, leverages its existing supply agreements with provincial liquor authorities, wholesalers and licensed retailers in nine Canadian jurisdictions, and provides consumers across the country with access to high-quality, compliant and quality assured cannabis products from passionate and committed micro-cultivators.

Zenabis will market these craft products under the Founders’ Reserve brand (www.foundersreserve.ca). This brand name reflects Zenabis’ desire to pay homage to the growers and advocates who played such a significant part in the establishment of the legal cannabis industry.

“As a licensed producer with a national distribution network for the adult use market, we are thrilled to bring the distinct and specialized products of licensed micro-cultivators to customers across Canada,” said Andrew Grieve, Chief Executive Officer of Zenabis. “Founders’ Reserve, and our Zen Craft Grow program, represent something new in the Canadian marketplace. This brand will provide safe, consistent and quality-assured products from commercially licensed growers, and the strains sold under this brand will reflect the dedication and passion that come from years of cultivation experience. Founders’ Reserve will provide highly coveted cannabis strains, developed with care by cultivators who have a deep commitment to their plants and their products. We are pleased to offer these thoughtfully produced artisanal products across Canada via our existing supply and distribution partners. Zen Craft Grow adds a new dimension to our product offerings, expands our brands through the addition of Founders’ Reserve, and demonstrates our commitment to a wide range of stakeholders, including micro-cultivators and consumers. We are excited about this program, and we intend to execute definitive, exclusive supply agreements with more than 20 licensed micro-cultivators and applicants with whom we have developed relationships.”

Sean Alston, Director of Zen Craft Grow for Zenabis, added, “With roughly 20 years experience in related markets, it is a pleasure to be involved with this program that sees the “founders” of our industry partner with Zenabis to create long-lasting relationships, enabling them to continue their craft in a legal and compliant manner. The feedback I have had from the growers involved in the program is that Zenabis’ support and dedication throughout the licensing process has been unbelievable and allows them to concentrate on what they do best, which is grow high-quality product.”

Zenabis’ Zen Craft Grow program will continue to pursue relationships with additional micro-cultivators across the country, with the ambition of bringing more diverse genetics and products to the wider Canadian adult-use market.

Founders’ Reserve adds another brand to Zenabis’ product offerings, joining the premium Namaste line, and the company’s core Zenabis medical products. Zenabis intends to further expand its brand offerings as facility expansion and licensing continues.

Zenabis has updated its information presentation to take into account this and other information. The updated presentation can be found here: https://www.zenabis.com/docs/zenabis-presentation.pdf

About Zenabis

Zenabis is a significant licensed cannabis cultivator of medical and adult use cannabis, and employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta and Langley, B.C.; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley provides Zenabis with 3.5 million square feet of facility space that can, upon full conversion, be dedicated to cannabis production.

If all facility space is fully built out and dedicated to production, Zenabis will own, and have access to, 660,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse space at its Langley facility (an additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business, to be converted at such a time that is beneficial to the strategic position of the company), strategically positioned on Canada’s coasts. These facilities, if fully converted for cannabis production, would have the design capacity to yield 479,700 kg of dried cannabis annually, for both national and international market distribution. The Zenabis brand name is used among the medical market, while Namaste is used to service the adult use market.

The management team at Zenabis has significant experience in finance, agriculture, technology, pharmaceutical sales, consumer packaged goods, international distribution and brand marketing.

Zenabis has established distribution relationships with provincial liquor authorities, wholesalers and licensed retailers in nine provinces and territories (British Columbia, Alberta, Saskatchewan, Manitoba, Quebec, New Brunswick, Nova Scotia, Prince Edward Island and the Yukon).

Forward Looking Information

This news release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding future supply to be provided by micro-cultivators, the intention to distribute such supply under the Founders’ Reserve brand, the pursuit of relationships with additional micro-cultivators, the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as “may”, “would”, “could”, “will”, “likely”, “believe”, “expect”, “anticipate”, “intend”, “plan”, “estimate” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis’ control. These risks, uncertainties and assumptions include, but are not limited to, those described in the Zenabis Management Information Circular dated November 23, 2018, a copy of which is available on SEDAR at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

For further information: Media Relations: media@zenabis.com, 1-844-523-8679; Investor Relations: Shobana Thaya, Zenabis Global Inc., Invest@zenabis.com, 1-844-523-8679; Andrew Grieve, Chief Executive Officer, 1-855-936-2247

Related Links

https://www.zenabis.com/

The post Zenabis Launches Zen Craft Grow: Program to Connect Micro-Cultivators to National Consumers appeared first on CannabisFN.

TORONTO, March 18, 2019 /CNW/ – TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) (“TerrAscend” or “The Company”) today announced preliminary fourth quarter and full year revenue ending December 31st, 2018 of CAD$4.8 millionⁱⁱ and CAD$6.6 millionⁱⁱⁱ, respectively. “We are thrilled with what we accomplished in 2018, and we are seeing increasing momentum across our businesses thus far in 2019. Our sales in Canada have been strong since the October launch of the adult-use market, and our Haven St. Premium brand is clearly resonating with provincial distributors and consumers. Meanwhile, in just four months since the initiation of our US strategy, TerrAscend has positioned itself to be one of the industry’s leading multi-state operators. We are excited by our progress towards becoming a leading global cannabinoid company and look forward to providing our full year 2019 outlook at the upcoming investor day on April 25^th“, said Matthew J. Johnson, President of TerrAscend Corp., and TerrAscend USA, Inc.

Details for the investor day will be forthcoming in a separate announcement.

 FOURTH QUARTER 2018 HIGHLIGHTS

• Completed capital reorganization with the continued support of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC), Canopy Rivers Corp. (TSXV: RIV) and funds controlled by Jason Wild, Chairman of the Company, allowing the Company to pursue US expansion.
• Awarded the right to a vertically integrated license in New Jersey, along with strategic minority partners. The operations will be in Northern New Jersey and include approximately 80,000 sq. ft. of cultivation and 40,000 sq. ft. of processing on the 16-acre campus. In addition, the company will be opening its first East Coast Apothecarium location in Philipsburg, NJ in Q4 2019.
• Completed the purchase of Grander Distribution, subsequently renamed Arise Bioscience, an industry leader in the development, manufacture, and distribution of hemp-derived products. The US$13,000,000 purchase price was an equal combination of cash and stock with the potential for additional consideration of up to US$10,000,000 based on revenue targets of US$35,000,000 in 2019 and US$50,000,000 in 2020. Arise’s innovative, whole-plant hemp extract products are made in the USA and are available for sale in ~10,000 retail locations worldwide.
• The Company continued to drive sales for its adult-use brand, Haven St. Premium Cannabis, a top-10 selling brand in the five Canadian provincial jurisdictions where it is sold.
• The Company secured a multi-year cannabis supply agreement with PharmHouse, a Canopy Rivers Joint Venture. PharmHouse will grow and supply cannabis to TerrAscend Canada from an existing 1.3 million square foot greenhouse where the production of flower, trim, and clones from 20% of the dedicated flowering space will be made available to TerrAscend Canada.
• Secured US$75 million credit facility with certain funds managed by JW Asset Management LLC, where Jason Wild is the President and Chief Investment Officer. The credit facility gives TerrAscend access to non-dilutive capital for acquisitions in the United States, as well as for general corporate and working capital purposes.
• Appointed Matthew J. Johnson as President, TerrAscend Corp and TerrAscend USA responsible for the overall operations of the business. Mr. Johnson, a seasoned healthcare industry executive with over 25 years of experience, has held multiple senior-level positions with several large medical device and pharmaceutical companies including Baxter, Abbott, and AbbVie.
• Announced the appointment of Craig Collard to the board of Directors. Mr. Collard has over 20 years of experience in the pharmaceutical industry with a track record of leadership, managing organizational change, and driving successful merger and acquisition activity. Mr. Collard is the CEO of Veloxis Pharmaceuticals (NASDAQ OMX: VELO), a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.

SUBSEQUENT EVENTS

• On February 11, 2019, the Company announced a series of transactions to facilitate the acquisition of The Apothecarium, a multi-state award winning retail dispensary network. As part of the transactions the Company acquired a vertically integrated operation in Nevada with cultivation, processing, and an Apothecarium dispensary, as well as Valhalla Confections, a provider of leading premium edible products. The Apothecarium’s four retail dispensaries in California and Nevada provide quality cannabis to both medical patients and adult-use customers with combined 2018 revenues in excess of US$45 million[iv]. The Apothecarium’s flagship location has been named the best-designed dispensary in the United States by Architectural Digest. The agreements are subject to regulatory approvals by various local and state authorities in each of the markets where the assets and licenses are held, as well as certain customary closing conditions.
• Construction of the Drug Preparation Premises (DPP) is now complete. The Company is pursuing provincial and federal licensing for the development and compounding of unique pharmaceutical formulations, including a manufacturer’s designation for cannabis products under the Cannabis Act and the Food and Drug Act.
• German authorities recently completed the GMP certification inspection of the Mississauga facility. The Company is preparing to export to Germany and other international markets once GMP certification is obtained.
• Construction on the Mississauga facility will be completed in Q2 2019, expanding cultivation by 140% and processing capacity by 800%. The facility will include manufacturing and processing for additional product formats.

About TerrAscend

TerrAscend is a biopharmaceutical and wellness company that is committed to quality products, brands, and services for the global cannabinoid market.  The Company participates in the medical and legal adult-use market in Canada and in US states where cannabis has been legalized for therapeutic or adult-use. TerrAscend operates a number of synergistic businesses, including Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products, Ascendant Laboratories Inc., a biotechnology and licensing Company committed to the continuous improvement of cannabinoid expressing plants, and Solace RX Inc., a proposed drug preparation premises focused on the development of novel formulations and dosage forms.

Caution Regarding Cannabis Operations in the United States

Investors should note that there are significant legal restrictions and regulations that govern the cannabis industry in the United States.  Cannabis remains a Schedule I drug under the US Controlled Substances Act, making it illegal under federal law in the United States to cultivate, distribute or possess cannabis in the United States.  Furthermore, financial transactions involving proceeds generated by, or intended to promote, cannabis-related business activities in the United States may form the basis for prosecution under applicable US federal money laundering legislation.

While the approach to enforcement of such laws by the federal government in the United States has trended toward non-enforcement against individuals and businesses that comply with medical or adult-use cannabis programs in states where such programs are legal, strict compliance with state laws with respect to cannabis will neither absolve TerrAscend of liability under US federal law, nor will it provide a defense to any federal proceeding which may be brought against TerrAscend.  Following any investment made by TerrAscend in operations in the United States, enforcement of federal laws in the United States will be a significant risk to the business of TerrAscend and any proceedings brought against TerrAscend thereunder may adversely affect TerrAscend’s operations and financial performance.

Forward Looking Information

This news release may contain “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions, and include statements with respect to the completion of the transactions discussed herein and the anticipated benefits thereof. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals and permits.

Although TerrAscend believes that the expectations and assumptions on which such forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because TerrAscend can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking statements are subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the inability of the parties to satisfy the conditions to closing set out in the definitive documentation in a timely manner or at all; risks related to federal, state, provincial, territorial, local and foreign government laws, rules and regulations, including federal and state laws in the United States relating to cannabis operations in the United States; TerrAscend’s ability to successfully integrate any acquired businesses in the future; and fluctuations in foreign currency exchange rate.

The statements in this press release are made as of the date of this release.  TerrAscend disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.  TerrAscend undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of TerrAscend, its securities, or financial or operating results (as applicable).

For further information: For more information regarding TerrAscend: Michael Nashat, Chief Executive Officer, IR@terrascend.com; Adam Kozak, Chief Financial Officer, IR@terrascend.com   

The post TerrAscend Provides Business Update Including Preliminary Fourth Quarter Revenue appeared first on CannabisFN.

TORONTO, March 18, 2019 (GLOBE NEWSWIRE) — Canopy Rivers Inc. (“Canopy Rivers”) (TSXV: RIV) and LeafLink, Inc. (“LeafLink”) are pleased to announce the establishment of LeafLink Services International ULC (“LeafLink International”), a new venture that exclusively licenses and leverages LeafLink’s dominant business-to-business (B2B) marketplace and supply chain technology platform for deployment throughout regulated international cannabis markets.

LeafLink is a software-as-a-service (SaaS) marketplace that simplifies the supply chain through its e-commerce platform. The company has a growing network of more than 950 cannabis brands, and penetration throughout ~2,800 cannabis retailers across 16 territories in the United States. LeafLink has established the single largest B2B marketplace for cannabis brands and facilitates more than US$900 million in gross merchandise value annually. Retailers use LeafLink for managing their wholesale inventory, enabling them to shop multiple vendors in one cart, view up-to-date product and brand menus, review historical and open orders, discover new products, and request samples. LeafLink further serves vendors by offering supplementary tools such as order management, a customer relationship management (CRM) platform, inventory tracking tools, and customized reporting systems, among other services.

“We have been very impressed with LeafLink’s deep market penetration and their understanding of cannabis companies’ needs and behaviors,” said Narbé Alexandrian, President of Canopy Rivers. “The number of brands and products within our new cannabis economy has been explosive, making it difficult for retailers to deal with multiple parties in an increasingly fragmented market. As regulated cannabis consumption and distribution proliferates around the world, LeafLink International will introduce the industry’s leading SaaS-enabled marketplace to the global stage to create a new standard for expediting the cannabis supply chain in regulated markets.”

By creating this new joint venture, Canopy Rivers continues to expand its exposure across the cannabis value chain through a capital-light, market-leading B2B platform that is immediately scalable across legal jurisdictions. Canopy Rivers intends to integrate its network of complementary cannabis companies and global reach to drive growth for LeafLink International and assist in developing and deploying this technology as it continues to increase its global footprint.

“We are excited to join forces with Canopy Rivers – combining our industry-leading, B2B marketplace technology with their expertise and strategic network in the global cannabis market,” said Ryan G. Smith, CEO and Co-founder of LeafLink. “Together, we are creating the first seamless e-commerce experience across the global cannabis supply chain to further empower members of the LeafLink community.”

Under the terms of the agreement, LeafLink has made an initial capital commitment of US$1 million along with an exclusive, royalty-free license for all non-US marketplaces for their proprietary B2B software platforms and service solutions. Canopy Rivers has committed an initial equity investment of US$2 million and has the option to invest an incremental US$6 million on preferred terms. LeafLink and Canopy Rivers hold approximately 82%, and 18%, respectively, of LeafLink International after the initial transaction. Both parties will work collaboratively on the continued development and deployment of the LeafLink technology platform throughout international marketplaces, having already launched in select Canadian markets.

About LeafLink:

LeafLink is the cannabis industry’s leading wholesale marketplace, serving more than 950 brands and  ~2,800 retailers across 16 territories with streamlined business tools such as an order management system, CRM, inventory tracking, and reporting systems, among others. Retailers who previously called, emailed, or texted dozens of sales representatives to place orders now save one day per week shopping all their cannabis brands in one LeafLink cart. Backed by venture capital firms and strategic investors such as Lerer Hippeau, Nosara and Casa Verde Capital, LeafLink has raised more than US$14 million to date, with its headquarters in New York City and Los Angeles.

About Canopy Rivers:

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers works collaboratively with Canopy Growth (TSX: WEED, NYSE: CGC) to identify strategic counterparties seeking financial and/or operating support. Canopy Rivers has developed an investment ecosystem of complementary cannabis operating companies that represent various segments of the value chain across the emerging cannabis sector. As the portfolio continues to develop, constituents will be provided with opportunities to work with Canopy Growth and collaborate among themselves, which Canopy Rivers believes will maximize value for its shareholders and foster an environment of innovation, synergy and value creation for the entire ecosystem.

Forward-Looking Statements

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Canopy Rivers with respect to future business activities and operating performance. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding: the ability of LeafLink International to launch its SaaS marketplace platform globally and create a new standard for expediting the cannabis supply chain in regulated markets; the scalability of LeafLink’s B2B platform; Canopy Rivers’ ability to integrate its network of complementary cannabis companies and global reach to drive growth for LeafLink International and assist in developing and deploying this technology as it continues to increase its global footprint; both parties will work collaboratively on the continued development and deployment of the LeafLink technology platform throughout international marketplaces; and other expectations for other economic, business, and/or competitive factors.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Canopy Rivers believes that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of Canopy Rivers. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: regulatory and licensing risks; the number of brands and retailers adopting LeafLink’s e-commerce platform; competition in the B2B supply chain space; the ability of LeafLink and Canopy Rivers to collaborate; changes in general economic, business and political conditions, including changes in the financial markets; the global regulatory landscape and enforcement related to cannabis, including political risks and risks relating to regulatory change; risks relating to anti-money laundering laws; compliance with extensive government regulation; public opinion and perception of the cannabis industry; and the risk factors set out in Canopy Rivers’ final short form prospectus dated February 21, 2019, filed with Canadian securities regulators and available on Canopy Rivers’ profile on SEDAR at www.sedar.com.

Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Canopy Rivers has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Canopy Rivers does not intend, and does not assume any obligation, to update this forward-looking information except as otherwise required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information, please contact:

Canopy Rivers Inc.

Karoline Hunter
Sr. Director, Investor Relations & Communications
E-mail: ir@canopyrivers.com

LeafLink

Rosie Mattio
RMPR
E-mail: Rosie@rosiemattiopr.com

The post LeafLink and Canopy Rivers Collaborate to Deploy Market-Leading B2B Software Platform Globally appeared first on CannabisFN.

OTTAWA, ON, March 18, 2019 /CNW/ – CannaRoyalty Corp. d/b/a Origin House (CSE: OH) (OTCQX: ORHOF) (“Origin House”), a North American cannabis products and brands company, announced today that its subsidiary Trichome Financial Corp. (“Trichome” or the “Company”) has entered into a C$2 million financing arrangement (the “Financing“) with C.G.S. Foods Inc. (dba Ganjika House) (“C.G.S.” or “Ganjika House“), a licensed Ontario cannabis retailer. Ganjika House was one of only 25 winners of the recent lottery conducted by the Alcohol and Gaming Commission of Ontario (“AGCO“) and is one of the first 5 to receive its Cannabis Retail Operator License and Retail Store Authorization. Ganjika House plans to open its location at 186 Main Street South in Brampton, Ontario, on April 1, 2019¹

• C.G.S. Foods Inc. (dba Ganjika House) was one of only 25 Ontario private cannabis retail lottery winners and is one of the first 5 to secure their Retail Operators License in Canada’s largest cannabis market – opening its location in Brampton, Ontario on April 1, 2019.[1] 
• Trichome has agreed to provide up to C$2 million comprised of a Revolving Credit Facility and Term Loan, both of which are fully secured.
• Trichome will receive warrants to acquire a minimum of 10.3% and a maximum of 13.3% of the common shares of Ganjika House, should the entire term loan be drawn.
• Ganjika House represents a unique platform to participate in retail industry growth and consolidation.
• Trichome’s go-public process is progressing, and the Company expects to close a private placement of subscription receipts in early April.

“The Trichome team has been impressed with the entrepreneurial spirit, commitment and vision of C.G.S. founder and sole shareholder Clint Seukeran,” said Michael Ruscetta, CEO of Trichome. “Ontario represents the largest retail opportunity in Canada. We believe C.G.S. possesses a significant first mover advantage in a constrained regulatory environment and is well-positioned to earn attractive returns on invested capital while being ideally positioned for industry growth and consolidation. Ganjika House represents a bold vision for cannabis retail and Trichome looks forward to partnering with Clint on this unique platform opportunity.”

Under the terms of the Financing, Trichome has agreed to provide C.G.S. with up to C$2 million for a period of two years, comprised of a Revolving Credit Facility and Term Loan, both of which are fully secured. The Financing provides Trichome with attractive rates of contractual cash flow and warrants to acquire, for a period of 5 years, a minimum of 10.3% and up to 13.3% of the common shares of C.G.S. should the entire term loan be drawn. C.G.S. may draw up to C$1 million on the Revolving Credit Facility against eligible inventory and will draw half of the Term Loan immediately.

Corporate Update

Marc Lustig, Chairman of Trichome and Chairman and CEO of founding shareholder Origin House commented, “Michael and the team at Trichome have already made significant progress since the closing of our first outside capital raise in September 2018. The opportunity to provide specialty finance solutions to companies operating in the growing and increasingly complex global cannabis industry is certainly more robust than our original business plan contemplated. Trichome has a focused pipeline of potential transactions, sourced through its proprietary network, and has started to deploy capital at an accelerated rate, with three new deals signed in the past four weeks. Led by a team with a proven track record of generating strong returns in both private and public markets, I am confident that Trichome will continue to drive value for shareholders while enabling investee companies to execute and grow.”

Go-public timing and financing:

On February 14, 2019, Trichome announced the launch of a non-brokered private placement of subscription receipts (link) (the “Private Placement“) in connection with its reverse take-over (the “RTO“) of 22 Capital Corp (TSXV: LFC.P). The Private Placement has been well-received by investors and the Company expects to close in early April. The Company expects a shareholder vote in respect of the RTO to occur by the end of the second quarter of 2019 with closing shortly thereafter, subject to receipt of all applicable approvals including the approval of the TSX Venture Exchange.

US Opportunities:

Given the size and rapid evolution of the cannabis landscape in the US, Trichome has received a substantial amount of inbound deal flow from US operators. With the core of the Company’s infrastructure in place and the ability to leverage Origin House’s significant US market knowledge, the Company believes that it is uniquely positioned to capitalize on credit market opportunities in the US market. While the Company’s pending transaction with 22 Capital on the TSX Venture Exchange currently prohibits such investment activities, Trichome management have been working with counsel to create structures that may enable the Company to pursue these opportunities while complying with its listing obligations. Trichome expects to be able to share additional information in the coming months.

About Trichome Financial Corp.
Trichome is a specialty finance company focused on providing flexible and creative capital solutions to the global legal cannabis market. Trichome was created to address the lack of credit availability in the large, growing and increasingly complex cannabis market. Founded by industry leaders Origin House, Stoic Advisory, and Sprott Inc. (TSX: SII), Trichome’s experienced management team has a unique edge to capitalize on proprietary deal flow and insight while developing a first mover advantage as a global cannabis focused specialty finance company. Trichome provides customized financing solutions across the industry value chain to support growth, capital expenditures, M&A, working capital and other needs. Transactions are typically structured to earn attractive rates of contractual cash flows, retain optionality on value creation and ensure return of capital. Leveraging the combined resources and knowledge of its founders and management, it is able to offer significant value-added financial, product, market and operational support to its partner companies. Trichome’s current assets are all based in Canada and it has no operations or assets in the United States. For more information, please visit us at www.trichomefinancial.com or @trichomefinance on Twitter.

About Origin House
Origin House is a growing cannabis products and brands company operating across key markets in the U.S. and Canada, with a strategic focus on becoming a preeminent global house of cannabis brands. The Company’s foundation is in California, the world’s largest regulated cannabis market, where it delivers over 130 branded cannabis products to the majority of licensed dispensaries. Origin House’s brand development platform is operated out of five licensed facilities located across California, and provides distribution, manufacturing, cultivation and marketing services for its brand partners. The Company is actively developing infrastructure to support the proliferation of its brands internationally, initially through its acquisition of Canadian retailer 180 Smoke. Origin House’s shares trade on the Canadian Securities Exchange (CSE) under the symbol “OH” and on the OTCQX under the symbol “ORHOF”. Origin House is the registered business name of CannaRoyalty Corp. For more information, visit www.originhouse.com.

Cautionary Note Regarding Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things: the expected closing of the Financing; returns to Trichome with respect to the Financing; future transactions of Trichome, their stage of development and their terms, including with respect to US opportunities; the origination of new transactions for Trichome; and the expected closing of each of the Financing and RTO and the timing of the shareholder vote in respect of the RTO. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive board, shareholder or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Trichome assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

SOURCE Origin House

For further information: Marc Lustig, Chairman and CEO, info@originhouse.com, 1-844-556-5070, www.originhouse.com; Jonathan Ross, CFA, LodeRock Advisors Inc., jon.ross@loderockadvisors.com, 416-283-0178; For Trichome Financial Corp.: Michael Ruscetta, Chief Executive Officer, (416) 561-2541, mruscetta@trichomefinancial.com

The post Origin House Subsidiary Trichome Financial Corp. Provides Financing to Licensed Ontario Cannabis Retailer and Provides Corporate Update appeared first on CannabisFN.

Ottawa, Ontario, March 14, 2019 (GLOBE NEWSWIRE) — LiveWell Canada Inc. (“LiveWell” or the “Company”), (CSE: LVWL), today announced it has finalized its CBD supply agreement with Tilray Inc. (NASDAQ: TLRY). LiveWell will supply Tilray with a monthly quantity of up to 300 kilograms of hemp-derived CBD isolate, or an equivalent amount of full-spectrum CBD extract. The Company expects to begin shipping Tilray its product during the second quarter of 2019.

As part of its diligence process, Tilray conducted laboratory testing on the Company’s product, as well as performing a site visit to the Company’s manufacturing facility in Eureka, Montana. The results of this due diligence met Tilray’s product and manufacturing standards.

“We’re thrilled to have the opportunity to partner with Tilray, one of the best known and most stringent companies in the cannabis and cannabinoid space,” said David Rendimonti, President and CEO of LiveWell Canada. “As we’ve previously outlined, one of our key priorities is capturing greater market share in wholesale. The finalization of this milestone agreement is a strong validator of our ability to produce and supply some of the highest-quality hemp-derived CBD available on the market. We look forward to a strong continuing relationship with Tilray.”

Under the terms of the agreement, LiveWell will initially supply Tilray with up to 150 kilograms per month of wholesale CBD isolate, or an equivalent amount of full-spectrum CBD extract, cultivated and processed from hemp, and meeting jurisdictional regulations. As of August 2019, the amount increases to 300 kilograms per month, with an option to increase to 500 kilograms per month. The Agreement is in effect until January 31, 2020, at which time it will automatically renew for successive 12-month terms unless either party has opted out of such renewal.

LiveWell continues to leverage its leadership in the wholesale CBD market. In addition, the Company aims to penetrate the consumer products space in the second half of 2019.

About LiveWell

LiveWell is an innovative Canadian health and wellness company focused on the advanced research of CBD and other cannabinoids. Utilizing state-of-the-art manufacturing facilities, LiveWell aims to cost-effectively extract and refine large quantities of hemp-derived CBD, better enabling it to develop, market and distribute wholesale and consumer products.

About Tilray®

Tilray is a global pioneer in the research, cultivation, production and distribution of cannabis and cannabinoids currently serving tens of thousands of patients and consumers in twelve countries spanning five continents.

Cautionary Note Regarding Forward-Looking Statements

This release includes forward-looking statements about the Company and its business. Often, but not always, forward-looking statements can be identified by the use of words such as “plan”, “continue”, “expect”, “schedule”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements (including negative variations) that certain events or conditions “may” or “will” occur. Such statements are based on the current expectations of management. The forward-looking events and circumstances discussed in this release may not occur by certain specified dates or at all and could differ materially as a result of unknown and known risk factors and uncertainties affecting the Company. Further, the Company cautions that this foregoing list of material factors is not exhaustive, and readers are encouraged to read all Risk Factors disclosed in the Company’s Management Discussion & Analysis dated October 26, 2018.

In respect of the forward-looking statements and information concerning the Tilray’s CBD supply agreement, and the timing for penetrating the consumer products space, the Company has provided such statements and information in reliance on certain assumptions that it believes are reasonable at this time.  

The forward-looking information contained in this press release represents expectations of the Company as of the date of this press release and accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While the Company may elect to, it does not undertake to update this information at any particular time except as required in accordance with applicable securities laws.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE LiveWell Canada Inc.

For more information, visit livewellcorp.com

Deborah Stokes
LiveWell Canada Inc.
819 576 3789
dstokes@livewellfoods.ca

Conrad Seguin
LiveWell Canada Inc.
437-226-7002
cseguin@livewellfoods.ca

David Rendimonti
LiveWell Canada Inc.
819-718-2042

The post LiveWell Finalizes Hemp CBD Supply Agreement with Tilray appeared first on CannabisFN.

VANCOUVER, March 18, 2019 /CNW/ – Harvest One Cannabis Inc. (“Harvest One” or the “Company”) (TSXV: HVT; OTCQX: HRVOF), through it’s wholly-owned subsidiary United Greeneries Ltd. (“United Greeneries”) today announced that it has entered into an agreement to become a medical cannabis supplier to Shoppers Drug Mart.

Under the terms of the agreement, Harvest One will supply Shoppers Drug Mart with Satipharm branded medical cannabis products. The products will be sold online, as Canadian regulations restrict the sale of medical cannabis in retail pharmacies.

The post Harvest One Announces Supply Agreement with Shoppers Drug Mart appeared first on CannabisFN.

The post Blissco Signs Supply Agreement with Alberta Gaming, Liquor and Cannabis (AGLC) appeared first on CannabisFN.

WAKEFIELD, Mass., March 18, 2019 /PRNewswire/ — Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF), a leading vertically integrated cannabis operator in the United States, today announced it has signed a definitive agreement to acquire Acres Cannabis (“Acres”). With 269,000 sq. ft. of operating cultivation facilities and further expansion as needed on its 37 acres of land in Amargosa Valley, Nevada, Acres operates the state’s largest cultivation facility, a state-of-the-art production and extraction lab and an immersive cannabis dispensary located in the city of Las Vegas, adjacent to the Strip, with a second dispensary under construction.

“The acquisition of Acres is a major step in expanding our vertical platform in Nevada. Acres operates a flagship dispensary in the heart of Las Vegas, complementing our existing assets in the state extremely well, and importantly, we can control the consistency, quality and production cost of our own cannabis products,” said Joseph Lusardi, CEO of Curaleaf. “We have built the most accessible, trusted and reliable cannabis brand and are extremely excited about the prospects in Nevada both for retail and wholesale activity.”

The addition of Acres’ cultivation platform will provide Curaleaf with 42,000 sq. ft. of functioning climate-controlled greenhouses and 227,000 sq. ft. of outdoor cultivation in Amargosa Valley. The site is currently under construction, adding another 133,000 sq. ft. of capacity. At over 400,000 sq. ft., the facility is expected to generate 100,000 pounds of dry flower per year at full scale. During the fourth quarter of 2018, Acres harvested over 5,000 pounds of flower.

Acres also operates an award winning 19,000 sq. ft. dispensary in Las Vegas, NV. The cannabis experiential store is open 24 hours a day, 7 days a week, and hosts America’s first marijuana farmers market every weekend. Steeped in the cannabis culture, the facilities offer a museum and open view processing kitchen where customers can view the processing of edibles and extracts. Acres also has a second dispensary in Ely, Nevada currently under construction and scheduled to open later this year.

John Mueller, CEO of Acres, commented, “Curaleaf’s management, vision and rapid expansion plans made them the natural fit for Acres.” Mueller added, “Acres believes Curaleaf is very well positioned to continue to be the largest cannabis operator in the U.S. giving our partners significant upside.”

Acres dispensaries are expected to be branded as Curaleaf by year end to further expand its leading footprint as the largest operator of single-branded dispensaries in the U.S.

The Acres acquisition significantly increases Curaleaf’s cultivation and manufacturing operations from which Curaleaf will supply its own flagship dispensary at 1736 Las Vegas Blvd in Las Vegas, scheduled to open in the second quarter of this year. Curaleaf will further continue the operation of its indoor grow facility, located near Las Vegas, producing consistently high-quality strains to be sold predominantly in Curaleaf stores in Nevada.

The transaction, valued at $70 million, with $25 million to be paid in cash, $45 million to be paid in Curaleaf stock and additional consideration to be paid if certain financial targets are exceeded, is subject to customary closing conditions and expected to close in 2019.

About Curaleaf Holdings

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf”) is the leading vertically integrated multi-state cannabis operator in the United States. It is a high-growth cannabis company with a national brand known for quality, trust and reliability. The company is positioned in highly populated, limited license states, and currently operates in 12 states with 42 dispensaries, 12 cultivation sites and 10 processing sites. Curaleaf has the executive expertise and research and development capabilities to provide leading service, selection, and accessibility across the medical and adult-use markets, as well as the CBD category through its Curaleaf Hemp brand.

About Acres

Acres Cannabis is driven by connecting with the cannabis culture, through one-of-a-kind experiences for customers at its 19,000 square foot dispensary in Las Vegas. With the largest marijuana cultivation facility in the state of Nevada, Acres’ vertically integrated agricultural, production and dispensary facilities bring together generations of horticultural experience to produce affordable products of the highest quality. For more information, please visit: https://acrescannabis.com/

FORWARD LOOKING STATEMENTS

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward looking information. Generally, forward-looking information may be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “proposed”, “is expected”, “budgets”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. There can be no assurance that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects the current beliefs of Curaleaf and is based on information currently available to Curaleaf and on assumptions that Curaleaf believes are reasonable. These assumptions include, but are not limited to, the anticipated benefits to Curaleaf of the transaction described above. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Curaleaf to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations; competition; changes in legislation affecting Curaleaf; the timing and availability of external financing on acceptable terms; and lack of qualified, skilled labor or loss of key individuals and the other factors identified in Curaleaf’s Listing Statement and its other public filings with the Canadian Securities Exchange. Although Curaleaf has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Curaleaf as of the date of this news release and, accordingly, is subject to change after such date.  However, Curaleaf expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Company Contact:
Curaleaf Holdings, Inc.
Christine Rigby, SVP, Investor Relations
crigby@curaleaf.com

Investor Contact:
Teneo
Brian Waldman, Senior Vice President
IR@curaleaf.com

Media Contact:
Teneo
Megan Bishop, Senior Vice President
Media@curaleaf.com

The post Curaleaf Continues its Aggressive Expansion West Through Strategic Acquisition in Nevada appeared first on CannabisFN.